Status:
TERMINATED
Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies
Lead Sponsor:
University of Michigan
Conditions:
Pancreas
Mass Lesion
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a randomized study that will enroll patients scheduled for an endoscopic ultrasound biopsy of a pancreas lesion to be in the heparin or saline group during the procedure. The purpose of this ...
Detailed Description
A total of 3 fine-needle biopsy passes will be performed on every procedure. The tissue specimens from each of the 3 passes will be collected in 3 separate jars of 10% formalin for tissue analysis. Th...
Eligibility Criteria
Inclusion
- Patient identified as having a possible solid pancreatic lesion on computed tomography or magnetic resonance
- Patient scheduled for Endoscopic ultrasound (EUS) for sampling of pancreatic mass
Exclusion
- known history of coagulopathy
- history of heparin allergy
- patients with evidence of vascular tumors on imaging
- Patients with history of chronic pancreatitis
- Pregnant patients
- Medically unstable patients
Key Trial Info
Start Date :
March 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 6 2021
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04764396
Start Date
March 12 2021
End Date
July 6 2021
Last Update
June 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109